A Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX-427) That Inhibits Heat Shock Protein 27 (Hsp27).

Trial Profile

A Phase 1 Study Evaluating A Second Generation Antisense Oligonucleotide (OGX-427) That Inhibits Heat Shock Protein 27 (Hsp27).

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Apatorsen (Primary) ; Docetaxel
  • Indications Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors OncoGenex Technologies
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2016 Results published in the Annals of Oncology.
    • 07 Jan 2013 Planned end date changed from 1 Dec 2011 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top